Identification and quantification of differentially methylated loci by the pyrosequencing technology.

Most available protocols for gene-specific DNA methylation analysis are either labor intensive, not quantitative, or limited to the measurement of the methylation status of only one or very few CpG positions. Pyrosequencing is a real-time sequencing technology that overcomes these limitations. After bisulfite modification of genomic DNA, a region of interest is amplified by polymerase chain reaction (PCR) with one of the two primers being biotinylated. The PCR-generated template is rendered single stranded and a pyrosequencing primer is annealed to analyze quantitatively CpGs within 120 bases. Advantages of the pyrosequencing technology are the ease of its implementation, the high quality and the quantitative nature of the results, and its ability to identify differentially methylated positions in close proximity. A minimum amount of 10 ng of bisulfite-treated DNA is necessary to obtain high reproducibility and avoid random amplification. The required DNA amount can be provided by an individual sample or a pool of samples to rapidly investigate the presence of variable DNA methylation patterns. The use of pools and serial pyrosequencing, that is, the successive use of several pyrosequencing primers on the same DNA template, significantly reduces cost, labor, and analysis time as well as saving precious DNA samples for the analysis of gene-specific DNA methylation patterns.

[1]  P. Laird,et al.  Rapid and quantitative method of allele-specific DNA methylation analysis. , 2006, BioTechniques.

[2]  L. Andersson,et al.  A sensitive method for detecting variation in copy numbers of duplicated genes. , 2003, Genome research.

[3]  T. Liloglou,et al.  Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer. , 2006, Human molecular genetics.

[4]  M. Ronaghi.  Pyrosequencing sheds light on DNA sequencing. , 2001, Genome research.

[5]  I. Gut,et al.  Expressional and Epigenetic Alterations of Placental Serine Protease Inhibitors: SERPINA3 Is a Potential Marker of Preeclampsia , 2007, Hypertension.

[6]  C. Howald,et al.  Detection of aneuploidies by paralogous sequence quantification , 2004, Journal of Medical Genetics.

[7]  J. Wasson.  Allele quantification and DNA pooling methods. , 2007, Methods in molecular biology.

[8]  I. Gut,et al.  De novo quantitative bisulfite sequencing using the pyrosequencing technology. , 2004, Analytical biochemistry.

[9]  N. Cross,et al.  Quantitative Analysis of SRNPN Gene Methylation by Pyrosequencing as a Diagnostic Test for Prader–Willi Syndrome and Angelman Syndrome , 2006 .

[10]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[11]  Peter Nürnberg,et al.  Evaluation of a potential epigenetic biomarker by quantitative methyl‐single nucleotide polymorphism analysis , 2002, Electrophoresis.

[12]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Alessandra Marini,et al.  Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.

[14]  A. Alderborn,et al.  Parallel DNA template preparation using a vacuum filtration sample transfer device. , 2003, BioTechniques.

[15]  J. Issa,et al.  Age-Related DNA Methylation Changes in Normal Human Prostate Tissues , 2007, Clinical Cancer Research.

[16]  K A Baggerly,et al.  Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. , 2003, BioTechniques.

[17]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Hober,et al.  Pyrosequencing: history, biochemistry and future. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[19]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Gut,et al.  Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. , 2003, BioTechniques.

[21]  I. Gut,et al.  Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools. , 2007, The Journal of molecular diagnostics : JMD.

[22]  Ivo Glynne Gut,et al.  Serial pyrosequencing for quantitative DNA methylation analysis. , 2006, BioTechniques.

[23]  D. Dietrich,et al.  Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA , 2006, Nucleic acids research.

[24]  I. Gut,et al.  Analysis of gene-specific DNA methylation patterns by pyrosequencing technology. , 2007, Methods in molecular biology.

[25]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[26]  István Simon,et al.  The BiSearch web server , 2006, BMC Bioinformatics.

[27]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.

[28]  J. Gillespie,et al.  Identification of a unique epigenetic sub‐microenvironment in prostate cancer , 2007, The Journal of pathology.

[29]  S. Clark,et al.  Detection and measurement of PCR bias in quantitative methylation analysis of bisulphite-treated DNA. , 1997, Nucleic acids research.